Answers are grounded in this paper and cite their sources.
Findings demonstrate TIPE2 silencing improves anti-tumor efficacy and T cell activation in pancreatic cancer, indicating potential for CAR-T therapy optimization.
Tumor necrosis factor-α-induced protein 8-like 2 (TIPE2) is an intracellular immune checkpoint protein known to suppress T cell activation and effector function. Despite its role in limiting T cell responses, CAR-T cells are prone to TIPE2-mediated inhibitory signaling. We therefore hypothesized that inhibiting this immune checkpoint would enhance CAR-T cell anti-tumor function. To overcome TIPE2-mediated negative regulation, we engineered a novel second-generation NKG2D-based CAR-T cell by incorporating TIPE2-targeting shRNA sequences directly into the CAR construct. TIPE2 knockdown efficiency in the CAR constructs was measured by qPCR and western blot analysis. The functional and mechanistic properties of TIPE2-downregulated CAR-T cells were evaluated in vitro by flow cytometry, including analysis of activation, cytotoxicity, exhaustion, apoptosis, proliferation, and differentiation. Antitumor efficacy was further validated in vivo using a preclinical pancreatic cancer mouse model. Flow cytometry analysis revealed that TIPE2-deficient CAR-T cells exhibited significantly higher expression of activation (CD69), degranulation (CD107a), cytotoxic (GzmB), and cytokine (IFN-γ) markers, resulting in more efficient tumor cell elimination compared to conventional CAR-T cells. TIPE2 silencing also reduced T cell exhaustion, lowered susceptibility to apoptosis, and enhanced proliferation when co-cultured with Panc-28 pancreatic cancer cells. Moreover, TIPE2 inhibition skewed CAR-T cells differentiation towards an effector phenotype (T EFF ), characterized by higher T-bet expression and reduced Eomes production. Mechanistically, these functional enhancements were mediated by increased NF-κB signaling, as confirmed by elevated p-p65 expression and functional reversal upon NF-κB inhibition. Consistently, TIPE2-deficient CAR-T cells exhibited significantly improved anti-tumor efficacy in vivo compared to wild-type CAR-T cells. We successfully developed TIPE2-downregulated NKG2D-CAR-T cells that exhibited enhanced activation and cytotoxicity while limiting apoptosis and exhaustion against NKG2D ligand-expressing pancreatic tumors, highlighting TIPE2 as a promising intracellular immune checkpoint target for optimizing CAR-T cell therapy in solid tumors.
No takes yet. Share an insight, caveat, or question.
Farooq et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: